Ask AI
ELCC 2025 Highlights

CME

Highlights of the 2025 European Lung Cancer Congress

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 27, 2025

Expiration: November 26, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, David Planchard, MD, PhD, discusses key studies for non-small-cell lung cancer (NSCLC) that were presented at the European Lung Cancer Congress (ELCC) 2025 Annual Meeting, with a focus on new clinical research of interest and clinical trial updates.

Please note that the slide thumbnails in this activity link to PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the education impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this education activity, please take a moment to answer the following questions.

How many people with NSCLC do you provide care for in a typical month?

Which of the following patient subpopulations with locally advanced or metastatic EGFR-mutated NSCLC and progression on first-line osimertinib may benefit from savolitinib plus osimertinib according to results from the phase II SAVANNAH trial reported at ELCC 2025?

Jane, a 64-year-old woman, was recently diagnosed with metastatic NSCLC with an EGFR mutation (ex19del). 

When discussing first-line treatment options, which of the following results would you tell her was reported from the phase III MARIPOSA trial of amivantamab plus lazertinib vs osimertinib?

An exploratory analysis of the phase III EMPOWER Lung01 trial evaluating continued cemiplimab with 4 cycles of chemotherapy after progression on first-line cemiplimab for patients with advanced NSCLC with PD-L1 ≥50% and no EGFR, ALK, and ROS1 mutations showed which of the following progression-free survival (PFS) results compared with historical PFS with chemotherapy alone after first-line anti–PD-1/PD-L1 therapy?